BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10365094)

  • 1. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
    Yazawa T; Kamma H; Fujiwara M; Matsui M; Horiguchi H; Satoh H; Fujimoto M; Yokoyama K; Ogata T
    J Pathol; 1999 Jan; 187(2):191-9. PubMed ID: 10365094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.
    Lu Y; Boss JM; Hu SX; Xu HJ; Blanck G
    J Immunol; 1996 Apr; 156(7):2495-502. PubMed ID: 8786310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
    Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
    Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
    Yazawa T; Ito T; Kamma H; Suzuki T; Okudela K; Hayashi H; Horiguchi H; Ogata T; Mitsui H; Ikeda M; Kitamura H
    Am J Pathol; 2002 Jul; 161(1):291-300. PubMed ID: 12107114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
    Meissner M; Whiteside TL; Kaufmann R; Seliger B
    Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
    Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
    Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion.
    Collinge M; Pardi R; Bender JR
    J Immunol; 1998 Aug; 161(4):1589-93. PubMed ID: 9712019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
    Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
    J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
    Cycon KA; Rimsza LM; Murphy SP
    Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line.
    Vedrenne J; Assier E; Pereno R; Bouzinba-Segard H; Azzarone B; Jasmin C; Charron D; Krief P
    Oncogene; 1997 Mar; 14(12):1453-61. PubMed ID: 9136989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation by thyroid hormone of human IFN-gamma-induced HLA-DR expression.
    Lin HY; Martino LJ; Wilcox BD; Davis FB; Gordinier JK; Davis PJ
    J Immunol; 1998 Jul; 161(2):843-9. PubMed ID: 9670962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
    Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
    Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells.
    Stam NJ; Kast WM; Voordouw AC; Pastoors LB; van der Hoeven FA; Melief CJ; Ploegh HL
    J Immunol; 1989 Jun; 142(11):4113-7. PubMed ID: 2541206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
    Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
    Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK; Frelinger JG; Ting JP
    J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
    Berghuis D; de Hooge AS; Santos SJ; Horst D; Wiertz EJ; van Eggermond MC; van den Elsen PJ; Taminiau AH; Ottaviano L; Schaefer KL; Dirksen U; Hooijberg E; Mulder A; Melief CJ; Egeler RM; Schilham MW; Jordanova ES; Hogendoorn PC; Lankester AC
    J Pathol; 2009 Jun; 218(2):222-31. PubMed ID: 19274709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.